Stewart DJ, Raaphorst GP, Yau J, Beaubien AR: Active vs. passive resistance, dose–response relationships, high dose chemotherapy, and resistance modulation: a hypothesis. Invest New Drugs. 1996, 14: 115-130.
CAS
PubMed
Google Scholar
Stewart DJ: Tumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancer. Crit Rev Oncol Hematol. 2010, 75: 173-234. 10.1016/j.critrevonc.2009.11.006.
Article
PubMed Central
PubMed
Google Scholar
Stewart DJ, Chiritescu G, Dahrouge S, Banerjee S, Tomiak EM: Chemotherapy dose–response relationships in non-small cell lung cancer and implied resistance mechanisms. Cancer Treat Rev. 2007, 33: 101-137. 10.1016/j.ctrv.2006.12.002.
Article
CAS
PubMed
Google Scholar
Stewart DJ: Mechanisms of resistance to cisplatin and carboplatin. Crit Rev Oncol Hematol. 2007, 63: 12-31. 10.1016/j.critrevonc.2007.02.001.
Article
PubMed
Google Scholar
Zhao R, Qiu A, Tsai E, Jansen M, Akabas MH, Goldman ID: The proton-coupled folate transporter: impact on pemetrexed transport and on antifolates activities compared with the reduced folate carrier. Mol Pharmacol. 2008, 74: 854-862. 10.1124/mol.108.045443.
Article
PubMed Central
CAS
PubMed
Google Scholar
Liang XJ, Shen DW, Gottesman MM: A pleiotropic defect reducing drug accumulation in cisplatin-resistant cells. J Inorg Biochem. 2004, 98: 1599-1606. 10.1016/j.jinorgbio.2004.05.015.
Article
CAS
PubMed
Google Scholar
Shen DW, Su A, Liang XJ, Pai-Panandiker A, Gottesman MM: Reduced expression of small GTPases and hypermethylation of the folate binding protein gene in cisplatin-resistant cells. Br J Cancer. 2004, 91: 270-276.
PubMed Central
CAS
PubMed
Google Scholar
Kim JS, Kim H, Shim YM, Han J, Park J, Kim DH: Aberrant methylation of the FHIT gene in chronic smokers with early stage squamous cell carcinoma of the lung. Carcinogenesis. 2004, 25: 2165-2171. 10.1093/carcin/bgh217.
Article
CAS
PubMed
Google Scholar
Oki Y, Aoki E, Issa JP: Decitabine–bedside to bench. Crit Rev Oncol Hematol. 2007, 61: 140-152. 10.1016/j.critrevonc.2006.07.010.
Article
PubMed
Google Scholar
Baylin SB, Herman JG, Graff JR, Vertino PM, Issa JP: Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv Cancer Res. 1998, 72: 141-196.
Article
CAS
PubMed
Google Scholar
Ghoshal K, Bai S: DNA methyltransferases as targets for cancer therapy. Drugs Today (Barc). 2007, 43: 395-422. 10.1358/dot.2007.43.6.1062666.
Article
CAS
Google Scholar
Chekhun VF, Lukyanova NY, Kovalchuk O, Tryndyak VP, Pogribny IP: Epigenetic profiling of multidrug-resistant human MCF-7 breast adenocarcinoma cells reveals novel hyper- and hypomethylated targets. Mol Cancer Ther. 2007, 6: 1089-1098. 10.1158/1535-7163.MCT-06-0663.
Article
CAS
PubMed
Google Scholar
Plumb JA, Strathdee G, Sludden J, Kaye SB, Brown R: Reversal of drug resistance in human tumor xenografts by 2'-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter. Cancer Res. 2000, 60: 6039-6044.
CAS
PubMed
Google Scholar
Chang X, Monitto CL, Demokan S, Kim MS, Chang SS, Zhong X, Califano JA, Sidransky D: Identification of hypermethylated genes associated with cisplatin resistance in human cancers. Cancer Res. 2010, 70: 2870-2879. 10.1158/0008-5472.CAN-09-3427.
Article
PubMed Central
CAS
PubMed
Google Scholar
Zeller C, Dai W, Steele NL, Siddiq A, Walley AJ, Wilhelm-Benartzi CS, Rizzo S, van der Zee A, Plumb JA, Brown R: Candidate DNA methylation drivers of acquired cisplatin resistance in ovarian cancer identified by methylome and expression profiling. Oncogene. 2012, 31: 4567-4576. 10.1038/onc.2011.611.
Article
CAS
PubMed
Google Scholar
Tanaka T, Bai T, Toujima S, Utsunomiya T, Matsuoka T, Kobayashi A, Yamamoto M, Sasaki N, Tanizaki Y, Utsunomiya H, Tanaka J, Yukawa K: Demethylation restores SN38 sensitivity in cells with acquired resistance to SN38 derived from human cervical squamous cancer cells. Oncol Rep. 2012, 27: 1292-1298.
PubMed Central
CAS
PubMed
Google Scholar
Vijayaraghavalu S, Peetla C, Lu S, Labhasetwar V: Epigenetic modulation of the biophysical properties of drug-resistant cell lipids to restore drug transport and endocytic functions. Mol Pharm. 2012, 9: 2730-2742. 10.1021/mp300281t.
Article
PubMed Central
CAS
PubMed
Google Scholar
Matei D, Fang F, Shen C, Schilder J, Arnold A, Zeng Y, Berry WA, Huang T, Nephew KP: Epigenetic resensitization to platinum in ovarian cancer. Cancer Res. 2012, 72: 2197-2205. 10.1158/0008-5472.CAN-11-3909.
Article
PubMed Central
CAS
PubMed
Google Scholar
Muerkoster SS, Werbing V, Koch D, Sipos B, Ammerpohl O, Kalthoff H, Tsao MS, Folsch UR, Schafer H: Role of myofibroblasts in innate chemoresistance of pancreatic carcinoma–epigenetic downregulation of caspases. Int J Cancer. 2008, 123: 1751-1760. 10.1002/ijc.23703.
Article
PubMed
Google Scholar
Shang D, Liu Y, Liu Q, Zhang F, Feng L, Lv W, Tian Y: Synergy of 5-aza-2'-deoxycytidine (DAC) and paclitaxel in both androgen-dependent and -independent prostate cancer cell lines. Cancer Lett. 2009, 278: 82-87. 10.1016/j.canlet.2008.12.034.
Article
CAS
PubMed
Google Scholar
Ding L, Qiu L, Zhang J, Guo B: Camptothecin-induced cell proliferation inhibition and apoptosis enhanced by DNA methyltransferase inhibitor, 5-aza-2'-deoxycytidine. Biol Pharm Bull. 2009, 32: 1105-1108. 10.1248/bpb.32.1105.
Article
CAS
PubMed
Google Scholar
Charlet J, Schnekenburger M, Brown KW, Diederich M: DNA demethylation increases sensitivity of neuroblastoma cells to chemotherapeutic drugs. Biochem Pharmacol. 2012, 83: 858-865. 10.1016/j.bcp.2012.01.009.
Article
CAS
PubMed
Google Scholar
Iwata H, Sato H, Suzuki R, Yamada R, Ichinomiya S, Yanagihara M, Okabe H, Sekine Y, Yano T, Ueno K: A demethylating agent enhances chemosensitivity to vinblastine in a xenograft model of renal cell carcinoma. Int J Oncol. 2011, 38: 1653-1661.
CAS
PubMed
Google Scholar
Onda K, Suzuki R, Tanaka S, Oga H, Oka K, Hirano T: Decitabine, a DNA methyltransferase inhibitor, reduces P-glycoprotein mRNA and protein expressions and increases drug sensitivity in drug-resistant MOLT4 and Jurkat cell lines. Anticancer Res. 2012, 32: 4439-4444.
CAS
PubMed
Google Scholar
San Jose-Eneriz E, Agirre X, Jimenez-Velasco A, Cordeu L, Martin V, Arqueros V, Garate L, Fresquet V, Cervantes F, Martinez-Climent JA, Heiniger A, Torres A, Prósper F, Roman-Gomez J: Epigenetic down-regulation of BIM expression is associated with reduced optimal responses to imatinib treatment in chronic myeloid leukaemia. Eur J Cancer. 2009, 45: 1877-1889. 10.1016/j.ejca.2009.04.005.
Article
CAS
PubMed
Google Scholar
Nabilsi NH, Broaddus RR, Loose DS: DNA methylation inhibits p53-mediated survivin repression. Oncogene. 2009, 28: 2046-2050. 10.1038/onc.2009.62.
Article
CAS
PubMed
Google Scholar
Fu S, Hu W, Iyer R, Kavanagh JJ, Coleman RL, Levenback CF, Sood AK, Wolf JK, Gershenson DM, Markman M, Hennessy BT, Kurzrock R, Bast RC: Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer. Cancer. 2011, 117: 1661-1669. 10.1002/cncr.25701.
Article
PubMed Central
CAS
PubMed
Google Scholar
Fang F, Balch C, Schilder J, Breen T, Zhang S, Shen C, Li L, Kulesavage C, Snyder AJ, Nephew KP, Matei DE: A phase 1 and pharmacodynamic study of decitabine in combination with carboplatin in patients with recurrent, platinum-resistant, epithelial ovarian cancer. Cancer. 2010, 116: 4043-4053. 10.1002/cncr.25204.
Article
PubMed Central
CAS
PubMed
Google Scholar
Kumari A, Srinivasan R, Wig JD: Effect of c-MYC and E2F1 gene silencing and of 5-azacytidine treatment on telomerase activity in pancreatic cancer-derived cell lines. Pancreatology. 2009, 9: 360-368. 10.1159/000212094.
Article
CAS
PubMed
Google Scholar
Tikoo K, Ali IY, Gupta J, Gupta C: 5-Azacytidine prevents cisplatin induced nephrotoxicity and potentiates anticancer activity of cisplatin by involving inhibition of metallothionein, pAKT and DNMT1 expression in chemical induced cancer rats. Toxicol Lett. 2009, 191: 158-166. 10.1016/j.toxlet.2009.08.018.
Article
CAS
PubMed
Google Scholar
Festuccia C, Gravina GL, D'Alessandro AM, Muzi P, Millimaggi D, Dolo V, Ricevuto E, Vicentini C, Bologna M: Azacitidine improves antitumor effects of docetaxel and cisplatin in aggressive prostate cancer models. Endocr Relat Cancer. 2009, 16: 401-413. 10.1677/ERC-08-0130.
Article
CAS
PubMed
Google Scholar
Ramachandran K, Gordian E, Singal R: 5-azacytidine reverses drug resistance in bladder cancer cells. Anticancer Res. 2011, 31: 3757-3766.
CAS
PubMed
Google Scholar
Li Y, Hu W, Shen DY, Kavanagh JJ, Fu S: Azacitidine enhances sensitivity of platinum-resistant ovarian cancer cells to carboplatin through induction of apoptosis. Am J Obstet Gynecol. 2009, 200: 177-e171-e179
PubMed
Google Scholar
Gordian E, Ramachandran K, Singal R: Methylation mediated silencing of TMS1 in breast cancer and its potential contribution to docetaxel cytotoxicity. Anticancer Res. 2009, 29: 3207-3210.
CAS
PubMed
Google Scholar
Crea F, Giovannetti E, Cortesi F, Mey V, Nannizzi S, Gallegos Ruiz MI, Ricciardi S, Del Tacca M, Peters GJ, Danesi R: Epigenetic mechanisms of irinotecan sensitivity in colorectal cancer cell lines. Mol Cancer Ther. 2009, 8: 1964-1973. 10.1158/1535-7163.MCT-09-0027.
Article
CAS
PubMed
Google Scholar
Kantarjian HM, O'Brien S, Huang X, Garcia-Manero G, Ravandi F, Cortes J, Shan J, Davisson J, Bueso-Ramos CE, Issa JP: Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience. Cancer. 2007, 109: 1133-1137. 10.1002/cncr.22508.
Article
PubMed Central
CAS
PubMed
Google Scholar
Issa JP, Garcia-Manero G, Giles FJ, Mannari R, Thomas D, Faderl S, Bayar E, Lyons J, Rosenfeld CS, Cortes J, Kantarjian HM: Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies. Blood. 2004, 103: 1635-1640. 10.1182/blood-2003-03-0687.
Article
CAS
PubMed
Google Scholar
Issa JP, Gharibyan V, Cortes J, Jelinek J, Morris G, Verstovsek S, Talpaz M, Garcia-Manero G, Kantarjian HM: Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate. J Clin Oncol. 2005, 23: 3948-3956. 10.1200/JCO.2005.11.981.
Article
CAS
PubMed
Google Scholar
Kantarjian H, Oki Y, Garcia-Manero G, Huang X, O'Brien S, Cortes J, Faderl S, Bueso-Ramos C, Ravandi F, Estrov Z, Ferrajoli A, Wierda W, Shan J, Davis J, Giles F, Saba HI, Issa JP: Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood. 2007, 109: 52-57. 10.1182/blood-2006-05-021162.
Article
CAS
PubMed
Google Scholar
Stewart DJ, Issa JP, Kurzrock R, Nunez MI, Jelinek J, Hong D, Oki Y, Guo Z, Gupta S, Wistuba II: Decitabine effect on tumor global DNA methylation and other parameters in a phase I trial in refractory solid tumors and lymphomas. Clin Cancer Res. 2009, 15: 3881-3888. 10.1158/1078-0432.CCR-08-2196.
Article
CAS
PubMed
Google Scholar
Braga EA, Loginov VI, Klimov EA, Kilosanidze G, Khodyrev DS, Kaganova NL, Kazybskaia TP, Ermilova VD, Gar'kavtseva RF, Pronina IV, Rud'ko OI, Zabarskiĭ ER, Sulimova GE, Kiselev LL: [Activation of RHOA gene transcription in epithelial tumors may be caused by gene amplification and/or demethylation of its promotor region]. Mol Biol (Mosk). 2006, 40: 865-877.
Article
CAS
Google Scholar
Rothem L, Stark M, Kaufman Y, Mayo L, Assaraf YG: Reduced folate carrier gene silencing in multiple antifolate-resistant tumor cell lines is due to a simultaneous loss of function of multiple transcription factors but not promoter methylation. J Biol Chem. 2004, 279: 374-384.
Article
CAS
PubMed
Google Scholar
Ma D, Huang H, Moscow JA: Down-regulation of reduced folate carrier gene (RFC1) expression after exposure to methotrexate in ZR-75-1 breast cancer cells. Biochem Biophys Res Comm. 2000, 279: 891-897. 10.1006/bbrc.2000.4019.
Article
CAS
PubMed
Google Scholar
Kane MA: The role of folates in squamous cell carcinoma of the head and neck. Cancer Detect Prev. 2005, 29: 46-53. 10.1016/j.cdp.2004.08.002.
Article
CAS
PubMed
Google Scholar
Piyathilake CJ, Johanning GL, Macaluso M, Whiteside M, Oelschlager DK, Heimburger DC, Grizzle WE: Localized folate and vitamin B-12 deficiency in squamous cell lung cancer is associated with global DNA hypomethylation. Nutr Cancer. 2000, 37: 99-107. 10.1207/S15327914NC3701_13.
Article
CAS
PubMed
Google Scholar
Stidley CA, Picchi MA, Leng S, Willink R, Crowell RE, Flores KG, Kang H, Byers T, Gilliland FD, Belinsky SA: Multivitamins, folate, and green vegetables protect against gene promoter methylation in the aerodigestive tract of smokers. Cancer Res. 2010, 70: 568-574. 10.1158/0008-5472.CAN-09-3410.
Article
PubMed Central
CAS
PubMed
Google Scholar
Finnell RH, Spiegelstein O, Wlodarczyk B, Triplett A, Pogribny IP, Melnyk S, James JS: DNA methylation in Folbp1 knockout mice supplemented with folic acid during gestation. J Nutr. 2002, 132 (8 Suppl): 2457S-2461S.
CAS
PubMed
Google Scholar
Zhang Y, Qu X, Jing W, Hu X, Yang X, Hou K, Teng Y, Zhang J, Liu Y: GSTP1 determines cis-platinum cytotoxicity in gastric adenocarcinoma MGC803 cells: regulation by promoter methylation and extracellular regulated kinase signaling. Anticancer Drugs. 2009, 20: 208-214. 10.1097/CAD.0b013e328322fbaa.
Article
CAS
PubMed
Google Scholar
Lee TB, Park JH, Min YD, Kim KJ, Choi CH: Epigenetic mechanisms involved in differential MDR1 mRNA expression between gastric and colon cancer cell lines and rationales for clinical chemotherapy. BMC Gastroenterol. 2008, 8: 33-10.1186/1471-230X-8-33.
Article
PubMed Central
PubMed
Google Scholar
Reed K, Hembruff SL, Sprowl JA, Parissenti AM: The temporal relationship between ABCB1 promoter hypomethylation, ABCB1 expression and acquisition of drug resistance. Pharmacogenomics J. 10: 489-504.
Orta ML, Mateos S, Cortes F: DNA demethylation protects from cleavable complex stabilization and DNA strand breakage induced by the topoisomerase type I inhibitor camptothecin. Mutagenesis. 2009, 24: 237-244. 10.1093/mutage/gep002.
Article
CAS
PubMed
Google Scholar
Liu ZG, Chen HY, Cheng JJ, Chen ZP, Li XN, Xia YF: Relationship between methylation status of ERCC1 promoter and radiosensitivity in glioma cell lines. Cell Biol Int. 2009, 33: 1111-1117. 10.1016/j.cellbi.2009.07.004.
Article
CAS
PubMed
Google Scholar
Tse KY, Liu VW, Chan DW, Chiu PM, Tam KF, Chan KK, Liao XY, Cheung AN, Ngan HY: Epigenetic alteration of the metallothionein 1E gene in human endometrial carcinomas. Tumour Biol. 2009, 30: 93-99. 10.1159/000218032.
Article
CAS
PubMed
Google Scholar
Stewart DJ, Kurzrock R: Cancer: the road to Amiens. J Clin Oncol. 2009, 27: 328-333.
Article
PubMed
Google Scholar
Shia J, Klimstra DS, Nitzkorski JR, Low PS, Gonen M, Landmann R, Weiser MR, Franklin WA, Prendergast FG, Murphy L, Tang LH, Temple L, Guillem JG, Wong WD, Paty PB: Immunohistochemical expression of folate receptor alpha in colorectal carcinoma: patterns and biological significance. Hum Pathol. 2008, 39: 498-505. 10.1016/j.humpath.2007.09.013.
Article
CAS
PubMed
Google Scholar
Yang AS, Estecio MR, Doshi K, Kondo Y, Tajara EH, Issa JP: A simple method for estimating global DNA methylation using bisulfite PCR of repetitive DNA elements. Nucleic Acids Res. 2004, 32: e38-10.1093/nar/gnh032.
Article
PubMed Central
PubMed
Google Scholar
Kroeger H, Jelinek J, Estecio MR, He R, Kondo K, Chung W, Zhang L, Shen L, Kantarjian HM, Bueso-Ramos CE, Issa JP: Aberrant CpG island methylation in acute myeloid leukemia is accentuated at relapse. Blood. 2008, 112: 1366-1373. 10.1182/blood-2007-11-126227.
Article
PubMed Central
CAS
PubMed
Google Scholar